Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed previous treatment with sofosbuvir regimens. In this op...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gut 2019-04, Vol.68 (4), p.721-728
Hauptverfasser:	Shiha, Gamal, Esmat, Gamal, Hassany, Mohamed, Soliman, Reham, Elbasiony, Mohamed, Fouad, Rabab, Elsharkawy, Aisha, Hammad, Radi, Abdel-Razek, Wael, Zakareya, Talaat, Kersey, Kathryn, Massetto, Benedetta, Osinusi, Anu, Lu, Sophia, Brainard, Diana M, McHutchison, John G, Waked, Imam, Doss, Wahid
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral drugs Cirrhosis Drug dosages Genotype & phenotype Genotypes Headache Hepatitis Hepatitis C Hepatology Infections Interferon Liver cirrhosis Patients Ribavirin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!